利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.028 秒)

    PROCESS FOR THE ENRICHMENT OF MELANOCYTES BY MEANS OF MODIFIED SURFACES
    3.
    发明申请
    PROCESS FOR THE ENRICHMENT OF MELANOCYTES BY MEANS OF MODIFIED SURFACES 审中-公开
    通过改性表面增强木质素的方法

    公开(公告)号：US20100015704A1

    公开(公告)日：2010-01-21

    申请号：US12447596

    申请日：2007-12-06

    申请人： Heike Mertsching ,  Petra Kluger ,  Herwig Brunner ,  Christian Oehr ,  Vincenzo Sciarratta

    发明人： Heike Mertsching ,  Petra Kluger ,  Herwig Brunner ,  Christian Oehr ,  Vincenzo Sciarratta

    IPC分类号： C12N5/08 ,  C12N5/00 ,  C12M3/00

    CPC分类号： C12N5/0626 ,  C12N2533/10 ,  C12N2533/12 ,  C12N2533/30

    摘要： The present invention relates to processes for obtaining melanocytes from a cell suspension, in particular from an epidermal cell suspension, by means of a culture vessel, wherein at least a part of the surface of the culture vessel facing the culture space, is modified, in particular functionalized, in particular by means of a low-pressure plasma process. Furthermore, the present invention relates to culture vessels which are modified, in particular functionalized, in particular by means of a low-pressure plasma process and are suitable for obtaining melanocytes and the use of such culture vessels for obtaining melanocytes.

    摘要翻译： 本发明涉及通过培养容器从细胞悬浮液，特别是表皮细胞悬浮液中获得黑素细胞的方法，其中培养容器面向培养空间的表面的至少一部分被修饰， 特别是通过低压等离子体工艺功能化。 此外，本发明涉及特别通过低压血浆方法改性，特别是官能化的培养容器，并且适用于获得黑素细胞和使用这种培养容器来获得黑素细胞。

    Hyphae-Specific Cell Wall Proteins Of Candida
    5.
    发明申请
    Hyphae-Specific Cell Wall Proteins Of Candida 审中-公开
    假丝酵母特异性细胞壁蛋白

    公开(公告)号：US20070196378A1

    公开(公告)日：2007-08-23

    申请号：US10593213

    申请日：2005-03-15

    申请人： Henrike Lotz ,  Herwig Brunner ,  Steffen Rupp

    发明人： Henrike Lotz ,  Herwig Brunner ,  Steffen Rupp

    IPC分类号： A61K48/00 ,  C12Q1/68 ,  G01N33/569 ,  C07H21/04 ,  A61K39/395 ,  C12N9/48 ,  C12N1/18 ,  C12N1/16 ,  C12N15/74

    CPC分类号： C07K14/40

    摘要： Nucleic acids that code a cell wall protein required for the hyphal development of Candida; fragments of the nucleic acids; vectors containing the nucleic acids or nucleic acid fragments; host cells containing the vectors; cell wall proteins coded by the nucleic acids; antibodies directed against the proteins; methods for producing the cell wall proteins; methods for characterizing and/or for detecting the hyphal stage of Candida; methods for detecting a Candida infection; methods for identifying substances having a therapeutic effect against diseases caused by Candida; diagnostic and pharmaceutical compositions containing the nucleic acid, nucleic acids fragments, vectors, host cells, proteins and/or antibodies directed against the cell wall protein; kits for conducting in-vitro indentation of the cell wall proteins, and; to the use of the nucleic acids, vectors, proteins or antibodies for diagnosing and treating Candida-caused diseases, i.e., producing diagnostic or pharmaceutical compositions.

    摘要翻译： 编码念珠菌菌丝体发育所需的细胞壁蛋白的核酸; 核酸片段; 含有核酸或核酸片段的载体; 含有载体的宿主细胞; 由核酸编码的细胞壁蛋白; 针对蛋白质的抗体; 生产细胞壁蛋白的方法; 表征和/或检测假丝酵母菌丝阶段的方法; 检测念珠菌感染的方法; 用于鉴定具有针对由念珠菌引起的疾病的治疗效果的物质的方法; 含有针对细胞壁蛋白的核酸，核酸片段，载体，宿主细胞，蛋白质和/或抗体的诊断和药物组合物; 用于进行细胞壁蛋白的体外压痕的试剂盒，和 涉及使用核酸，载体，蛋白质或抗体来诊断和治疗念珠菌引起的疾病，即产生诊断或药物组合物。

    Metal solution-diffusion membrane and method for producing the same
    6.
    发明申请
    Metal solution-diffusion membrane and method for producing the same 失效
    金属溶液扩散膜及其制造方法

    公开(公告)号：US20050011359A1

    公开(公告)日：2005-01-20

    申请号：US10484774

    申请日：2002-07-03

    申请人： Xiulian Pan ,  Norbert Stroh ,  Herwig Brunner

    发明人： Xiulian Pan ,  Norbert Stroh ,  Herwig Brunner

    IPC分类号： B01D53/22 ,  B01D69/08 ,  B01D69/12 ,  B01D71/02 ,  C01B3/50

    CPC分类号： B01D67/0083 ,  B01D53/22 ,  B01D63/02 ,  B01D69/08 ,  B01D69/12 ,  B01D71/022 ,  B01D2313/23 ,  B01D2323/08 ,  B01D2325/04 ,  C01B3/505 ,  C01B2203/0405 ,  C01B2203/0465 ,  Y10S55/05

    摘要： The present invention relates to a metal solution-diffusion membrane of a macroporous base on which a thin metal membrane layer (3) is formed. In the present membrane, the base comprises a hollow fiber (1) with a metal material containing an intermediate layer (2) being formed between the hollow fiber (1) and the metal membrane layer (3). The invention further relates to a method for producing such a metal solution-diffusion membrane in which the intermediate layer (2) serves to provide nuclei for the subsequent currentless deposition of the metal layer (3). The present metal solution-diffusion membrane can be realized with a very thin metal membrane layer with high permeability and possesses great long-term stability as well as a great separation surface/volume ratio.

    摘要翻译： 本发明涉及形成有金属薄膜层（3）的大孔基材的金属溶液 - 扩散膜。 在本膜中，基底包括中空纤维（1），其中含有在中空纤维（1）和金属膜层（3）之间形成的中间层（2）的金属材料。 本发明还涉及一种用于制造这种金属溶液 - 扩散膜的方法，其中中间层（2）用于提供用于金属层（3）的随后无电流沉积的核。 本发明的金属溶液 - 扩散膜可以用非常薄的金属膜层实现，具有很高的渗透性，并且具有很好的长期稳定性以及很大的分离表面/体积比。

    Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies
    8.
    发明授权
    Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies 失效
    用作激动剂和/或淀粉样蛋白形成和细胞毒性抑制剂以及用于阿尔茨海默氏病，II型糖尿病和海绵状脑病的肽

    公开(公告)号：US06359112B2

    公开(公告)日：2002-03-19

    申请号：US09097194

    申请日：1998-06-12

    申请人： Afroditi Kapurniotu ,  Jürgen Bernhagen ,  Herwig Brunner

    发明人： Afroditi Kapurniotu ,  Jürgen Bernhagen ,  Herwig Brunner

    IPC分类号： C07K412

    CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K5/1008 ,  C07K14/4711 ,  C07K14/575

    摘要： Certain peptide molecules can be used as the basic structures (template molecules) for inhibiting and analysing amyloid formation and cytotoxicity in amyloid illnesses. These peptides have an effect on the molecules which are responsible for the amyloid illnesses (for their part amyloid-forming peptides and proteins). The peptides are thus either inhibitors themselves or agonists of amyloid formation and cytotoxicity or can serve as a template for identifying and producing further inhibitors and agonists and can be used as molecular tools during analysis. The peptide molecules have generally 3-15 amino acids, and preferably a maximum of 10 amino acids, and at least an active peptide sequence GA, preferably GAI, and even more preferably one selected from the group consisting of GAIL, SEQ ID NO: 1; FGAIL, SEQ ID NO: 2; NFGAIL, SEQ ID NO: 3; NNFGAIL, SEQ ID NO: 4; SNNFGAIL, SEQ ID NO: 5; NFGAILSS, SEQ ID NO: 6; SNNFGAILSS, SEQ NO: 7; or the group consisting of GAII, SEQ ID NO: 8; KGAII, SEQ ID NO: 9; NKGAII, SEQ ID NO: 10; SNKGAII, SEQ ID NO: 11; GSNKGAII, SEQ ID NO: 12; NKGAIIGL, SEQ ID NO: 13; GSNKGAIIGL, SEQ ID NO: 14; or the group consisting of GAVV, SEQ ID NO: 15; AGAVV, SEQ ID NO: 16; VAAGAVV, SEQ ID NO: 17; HVAAGAVV, SEQ ID NO: 18; AAGAVVGG, SEQ ID NO: 19; HVAAGAVVGG, SEQ ID NO: 20; AAGAVV, SEQ ID NO: 21. The peptide sequence generally has at least one hydrogen molecule, and preferably every second hydrogen molecule, of an amide bond replaced by a methyl group.

    摘要翻译： 某些肽分子可用作抑制和分析淀粉样蛋白疾病中淀粉样蛋白形成和细胞毒性的基本结构（模板分子）。 这些肽对负责淀粉样蛋白病（对于其部分淀粉样蛋白形成肽和蛋白质）的分子具有影响。 因此，肽是抑制剂本身或淀粉样蛋白形成和细胞毒性的激动剂，或者可以用作鉴定和产生其它抑制剂和激动剂的模板，并且可以在分析过程中用作分子工具。 肽分子通常具有3-15个氨基酸，优选最多10个氨基酸，和至少一个活性肽序列GA，优选GAI，甚至更优选选自GAIL，SEQ ID NO：1 ; FGAIL，SEQ ID NO：2; NFGAIL，SEQ ID NO：3; NNFGAIL，SEQ ID NO：4; SNNFGAIL，SEQ ID NO：5; NFGAILSS，SEQ ID NO：6; SNNFGAILSS，SEQ NO：7; 或由GAII，SEQ ID NO：8组成的组; KGAII，SEQ ID NO：9; NKGAII，SEQ ID NO：10; SNKGAII，SEQ ID NO：11; GSNKGAII，SEQ ID NO：12; NKGAIIGL，SEQ ID NO：13; GSNKGAIIGL，SEQ ID NO：14; 或由GAVV，SEQ ID NO：15组成的组; AGAVV，SEQ ID NO：16; VAAGAVV，SEQ ID NO：17; HVAAGAVV，SEQ ID NO：18; AAGAVVGG，SEQ ID NO：19; HVAAGAVVGG，SEQ ID NO：20; AAGAVV，SEQ ID NO：21.肽序列通常具有由甲基取代的酰胺键至少一个氢分子，优选每第二个氢分子。

    Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo
    9.
    发明授权
    Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo 失效
    超强降钙素类似物在体内大大增加了低钙血症作用

    公开(公告)号：US06265534B1

    公开(公告)日：2001-07-24

    申请号：US09137389

    申请日：1998-08-20

    申请人： Afroditi Kapurniotu ,  Jurgen Bernhagen ,  Herwig Brunner

    发明人： Afroditi Kapurniotu ,  Jurgen Bernhagen ,  Herwig Brunner

    IPC分类号： A61K3823

    CPC分类号： C07K14/585 ,  A61K38/00

    摘要： Superpotent calcitonin analogs have greatly increased hypocalcemic action in vivo. These calcitonins and calcitonin derivatives are employed for the therapy of, for example, osteoporosis, Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the positions 17 and 21. By means of suitable choice of the amino acids present in these positions an 18-membered or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human calcitonin analog) is a cyclo17,21-[Asp17, Orn21]-hCt having a 19-membered ring structure between the lactam-bridged Asp17 and Orn21.

    摘要翻译： 超强降钙素类似物在体内大大增加了低钙血症的作用。 这些降钙素和降钙素衍生物用于治疗例如骨质疏松症，佩吉特氏病或高钙血症。 降钙素和降钙素衍生物的区别在于存在于位置17和21中的氨基酸的桥接。通过适当选择存在于这些位置的氨基酸，产生18元或19元环。 该环导致增加的构象稳定性和增加的降钙素的活性。 特别合适的hCt（人降钙素类似物）是在内酰胺桥连的Asp17和Orn21之间具有19-元环结构的环17,21- [Asp17，Orn21] -hCt。